Far Beyond Weight: The New Discovery About Weight-Loss Drugs

A major new study presented at the American Heart Association conference found that GLP-1 weight-loss drugs reduce the risk of developing diabetes by 31% in adults with prediabetes and obesity, and reduce the risk of death by 41%, compared to metformin. The researchers emphasize that this is an observational study and the findings are preliminary.

A large observational study presented at the American Heart Association conference points to significant health benefits of GLP-1 weight-loss drugs beyond weight reduction. Based on data from over 256,000 patients, the study found that among adults with obesity and prediabetes, taking these drugs reduced the risk of developing type 2 diabetes by 31% and the risk of all-cause mortality by 41%, compared to treatment with metformin. Additionally, there was a 20% reduction in stroke risk and a 15% reduction in heart attack risk. However, the researchers stress that this is an observational study showing a statistical association but not proving cause and effect, and that the findings have not yet undergone full peer review. It is also noted that no medication changes should be made without consulting a doctor, and that diet and exercise remain the foundation of treatment.